Novel CAR-T induces response prior to HSCT in younger patients with advanced AML


Sumary of Novel CAR-T induces response prior to HSCT in younger patients with advanced AML:

  • A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study..
  • Results of the trial — presented during the virtual ASCO Annual Meeting — may indicate a role for the CAR T-cell therapy as an effective bridging strategy before hematopoietic stem cell transplant, according to the researchers..
  • Zhang said, adding that several preclinical studies have demonstrated the antitumor efficacy of targeting CLL1 in humanized models..
  • Eight patients received CLL1-targeted CAR T cells, whereas three patients received a bispecific CAR that also targeted the CD33 protein..
  • Patients received the dual-targeted CLL1/CD33 CAR T cells if they had lower expression of CLL1, Zhang told Healio..
  • In each case, he added, the scientific team discussed the proper construct to use before proceeding to CAR T-cell therapy for AML..
  • Patients received a lymphodepletion chemotherapy regimen of cyclophosphamide and fludarabine, followed by a single IV infusion of 0.3 × 106/kg to 1 × 106/kg CAR T cells..
  • The three patients who received CLL1/CD33-directed CAR T cells had either grade 1 or grade 2 hepatoxicity that was not experienced by any patient who received CLL1-directed CAR T cells….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.